| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
47,262,000 |
| Market
Cap: |
24.12(B) |
| Last
Volume: |
382,753 |
Avg
Vol: |
445,594 |
| 52
Week Range: |
$274.7 - $510.94 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Other |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 1207 |
| Guru Rank Value : -1 |
| Guru Occurances : 3 |
|
|
|
|
|
| |
|
Company Profile United Therapeutics is a biotechnology company. Through its subsidiary, Lung Biotechnology PBC, Co. is focused on addressing the acute national shortage of transplantable lungs and other organs with a variety of technologies that either delay the need for such organs or expand the supply. Co. markets and sells the following commercial therapies to treat pulmonary arterial hypertension: Remodulin® (treprostinil) Injection; Tyvaso® (treprostinil) Inhalation Solution; Orenitram® (treprostinil) Extended-Release Tablets; and Adcirca® (tadalafil) Tablets. In the U.S., Co. also markets and sells an oncology product, Unituxin® (dinutuximab) Injection, for the treatment of high-risk neuroblastoma.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
693,477 |
917,412 |
1,155,527 |
2,304,298 |
| Total Sell Value |
$317,661,243 |
$402,811,556 |
$480,823,720 |
$813,433,089 |
| Total People Sold |
7 |
9 |
13 |
14 |
| Total Sell Transactions |
85 |
114 |
145 |
324 |
| End Date |
2025-09-25 |
2025-06-24 |
2024-12-24 |
2023-12-25 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Malcolm Jan |
|
– • – |
2025-12-23 |
4 |
AS |
$512.12 |
$25,606 |
D/D |
(50) |
420 |
|
- |
|
| Sullivan Louis |
|
– • – |
2025-12-22 |
4 |
S |
$511.22 |
$3,047,201 |
I/I |
(5,950) |
0 |
|
- |
|
| Sullivan Louis |
|
– • – |
2025-12-22 |
4 |
OE |
$183.98 |
$1,219,339 |
I/I |
5,950 |
5,950 |
|
- |
|
| Rothblatt Martine A |
Chairperson & CEO |
• • – |
2025-12-19 |
4 |
AS |
$505.45 |
$1,014,143 |
D/D |
(2,000) |
130 |
|
- |
|
| Rothblatt Martine A |
Chairperson & CEO |
• • – |
2025-12-19 |
4 |
OE |
$120.26 |
$240,520 |
D/D |
2,000 |
2,130 |
|
- |
|
| Rothblatt Martine A |
Chairperson & CEO |
• • – |
2025-12-18 |
4 |
AS |
$507.24 |
$2,035,488 |
D/D |
(4,000) |
130 |
|
2% |
|
| Rothblatt Martine A |
Chairperson & CEO |
• • – |
2025-12-18 |
4 |
OE |
$120.26 |
$481,040 |
D/D |
4,000 |
4,130 |
|
- |
|
| Thompson Tommy G |
|
– • – |
2025-12-18 |
4 |
S |
$500.59 |
$455,533 |
D/D |
(910) |
8,480 |
|
-2% |
|
| Thompson Tommy G |
|
– • – |
2025-12-18 |
4 |
OE |
$101.80 |
$92,638 |
D/D |
910 |
9,390 |
|
- |
|
| Rothblatt Martine A |
Chairperson & CEO |
• • – |
2025-12-17 |
4 |
AS |
$500.52 |
$2,004,147 |
D/D |
(4,000) |
130 |
|
1% |
|
| Rothblatt Martine A |
Chairperson & CEO |
• • – |
2025-12-17 |
4 |
OE |
$120.26 |
$481,040 |
D/D |
4,000 |
4,130 |
|
- |
|
| Rothblatt Martine A |
Chairperson & CEO |
• • – |
2025-12-16 |
4 |
AS |
$492.49 |
$1,973,820 |
D/D |
(4,000) |
130 |
|
3% |
|
| Rothblatt Martine A |
Chairperson & CEO |
• • – |
2025-12-16 |
4 |
OE |
$120.26 |
$481,040 |
D/D |
4,000 |
4,130 |
|
- |
|
| Benkowitz Michael |
PRESIDENT AND COO |
• – – |
2025-12-15 |
4 |
AS |
$491.18 |
$11,166,722 |
I/I |
(22,500) |
0 |
|
3% |
|
| Benkowitz Michael |
PRESIDENT AND COO |
• – – |
2025-12-15 |
4 |
OE |
$117.76 |
$5,491,040 |
I/I |
22,500 |
7,875 |
|
- |
|
| Rothblatt Martine A |
Chairperson & CEO |
• • – |
2025-12-15 |
4 |
AS |
$491.77 |
$1,978,869 |
D/D |
(4,000) |
130 |
|
3% |
|
| Rothblatt Martine A |
Chairperson & CEO |
• • – |
2025-12-15 |
4 |
OE |
$120.26 |
$481,040 |
D/D |
4,000 |
4,130 |
|
- |
|
| Patusky Christopher |
|
– • – |
2025-12-15 |
4 |
S |
$495.95 |
$495,954 |
D/D |
(1,000) |
1,490 |
|
-3% |
|
| Patusky Christopher |
|
– • – |
2025-12-15 |
4 |
OE |
$101.80 |
$101,800 |
D/D |
1,000 |
2,490 |
|
- |
|
| Edgemond James |
CFO AND TREASURER |
• – – |
2025-12-15 |
4 |
AS |
$491.53 |
$1,742,193 |
D/D |
(3,517) |
8,142 |
|
3% |
|
| Edgemond James |
CFO AND TREASURER |
• – – |
2025-12-15 |
4 |
OE |
$146.03 |
$513,588 |
D/D |
3,517 |
11,659 |
|
- |
|
| Rothblatt Martine A |
Chairperson & CEO |
• • – |
2025-12-12 |
4 |
AS |
$489.95 |
$1,962,783 |
D/D |
(4,000) |
130 |
|
5% |
|
| Rothblatt Martine A |
Chairperson & CEO |
• • – |
2025-12-12 |
4 |
OE |
$120.26 |
$481,040 |
D/D |
4,000 |
4,130 |
|
- |
|
| Malcolm Jan |
|
– • – |
2025-12-11 |
4 |
AS |
$482.98 |
$24,149 |
D/D |
(50) |
470 |
|
6% |
|
| Rothblatt Martine A |
Chairperson & CEO |
• • – |
2025-12-11 |
4 |
AS |
$483.12 |
$1,935,879 |
D/D |
(4,000) |
130 |
|
6% |
|
2279 Records found
|
|
Page 1 of 92 |
|
|
3.35 (0.65%) 
